- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00272077
Insulin Glargine in Type 2 Diabetes Mellitus
Pilot Study on Glycaemic Variability in Type 2 Diabetes Mellitus Patients With Basal Insulin and Fixed Combo Oral Antidiabetic Treatment.
Primary objective:
To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).
Secondary objectives:
The secondary objectives are the assessment of: changes in glycaemic control (HbA1C), frequency of hypoglycaemias, changes in weight, final insulin dose, changes in lipid parameters, changes in urinary albumin-to-creatinine ratio, profile of patient which best fits each of the algorithms with the dependent variable of change in HbA1C and independent variables of age, gender, race, tobacco use, diabetes complications, initial HbA1C, initial weight, duration of diabetes mellitus, general education and diabetes education.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of type 2 diabetes mellitus for at least 5 years;
- Treatment with oral antidiabetic drugs in fixed combination (Combo, i.e. glibenclamide 2.5 mg + metformin 400 mg, 2 or 3 tablets, at stable dose in the last 3 months);
- HbA1c >= 8% and <= 11%;
- Body mass index (BMI) > 27 and < 35 kg/m2;
- Willingness and demonstrated ability to inject insulin;
- Demonstrated ability and willingness to perform self-monitoring of blood glucose (SMBG);
Exclusion criteria:
- Patients diagnosed with type 1 insulin dependent diabetes;
- Patients with latent autoimmune diabetes of adults (LADA), defined as fasting C-peptide levels < 1 ng/ml;
- Cardiac status NYHA III-IV;
- Impaired renal function as shown by (but not limited to) serum creatinine >= 1.5 mg/dl for males or >= 1.4 mg/dl for females;
- Planned pregnancy, pregnant or lactating females;
- Failure to use adequate contraception (women of current reproductive potential only);
- Any current malignancy, previous breast cancer, or malignant melanoma within the past 5 years;
- Diagnosis of dementia
- Hypersensitivity to insulin or any of their components or to metformin;
- Current or previous insulin therapy other than during hospitalisations;
- Inability or unwillingness to continue metformin at study dosages throughout the study;
- Treatment with intermittent doses of systemic steroids or large doses of inhaled steroids for the past one year (fixed doses for the past 6 months is acceptable providing there is no plan to change the dosage regime);
- Stroke, Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), Percutaneous Transluminal Coronary Angioplasty (PTCA), or Angina Pectoris within the last 12 months;
- History of drug or alcohol abuse;
- Receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SMBG values
Time Frame: during the last 4 weeks before visit 3 (end of cycle 1) and visit 4
|
during the last 4 weeks before visit 3 (end of cycle 1) and visit 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
glycaemic control (HbA1c, fasting blood glucose, insulin and C-peptide),
Time Frame: During the study conduct
|
During the study conduct
|
frequency of hypoglycaemias
Time Frame: During the study conduct
|
During the study conduct
|
body weight
Time Frame: During the study conduct
|
During the study conduct
|
final insulin dose
Time Frame: During the study conduct
|
During the study conduct
|
lipid profile (serum total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides)
Time Frame: During the study conduct
|
During the study conduct
|
urinary albumin-to-creatinine ratio
Time Frame: During the study conduct
|
During the study conduct
|
standard meal test
Time Frame: during the study conduct
|
during the study conduct
|
results of CGMS
Time Frame: During the study conduct
|
During the study conduct
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOE901_3509
- EudraCT # : 2004-002730-19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
HighTide Biopharma Pty LtdRecruitingT2DM (Type 2 Diabetes Mellitus)China
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
Clinical Trials on Insuline glargine
-
SanofiTerminated
-
Novo Nordisk A/SRecruitingObesity | Diabetes Mellitus, Type 2United States, Spain, Portugal, Italy, Greece, Romania, Slovakia, Czechia, South Africa, Ukraine
-
Lannett Company, Inc.Parexel; FARMOVS (Pty) LtdCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusSouth Africa
-
RISE Study GroupNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Emory UniversitySanofiCompletedDiabetes MellitusUnited States
-
WockhardtCompletedType1 DiabetesUnited States
-
Xijing HospitalCompletedType 2 Diabetes MellitusChina
-
University of Colorado, DenverSanofiCompleted